1. Search Result
Search Result
Results for "

ASA

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

2

Natural
Products

2

Recombinant Proteins

14

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14654
    Aspirin
    25+ Cited Publications

    Acetylsalicylic acid; ASA

    COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin
  • HY-10964
    Vadimezan
    Maximum Cited Publications
    59 Publications Verification

    DMXAA; ASA-404

    STING IFNAR Influenza Virus Infection Cancer
    Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
    Vadimezan
  • HY-14654R
    Aspirin (Standard)
    25+ Cited Publications

    Acetylsalicylic acid(Standard); ASA (Standard)

    Reference Standards COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin (Standard) is the analytical standard of Aspirin. This product is intended for research and analytical applications. Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin (Standard)
  • HY-14654S1

    Acetylsalicylic acid-d4; ASA-d4

    Isotope-Labeled Compounds COX Autophagy Mitophagy Virus Protease NF-κB Apoptosis Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin-d4 is the deuterium labeled Aspirin (HY-14654). Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin-d4
  • HY-14654S

    Acetylsalicylic acid-d3; ASA-d3

    Isotope-Labeled Compounds COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin-d3 is the deuterium labeled Aspirin (HY-14654). Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin-d3
  • HY-143704S

    Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride

    PPAR NF-κB PAK Metabolic Disease
    5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
    5-Aminosalicylic acid-13C6 hydrochloride
  • HY-10964R

    DMXAA (Standard); ASA-404 (Standard)

    STING IFNAR Influenza Virus Infection Cancer
    Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
    Vadimezan (Standard)
  • HY-14654B

    Acetylsalicylic acid DL-lysine; ASA DL-lysine

    COX NF-κB p38 MAPK Cardiovascular Disease Others Inflammation/Immunology
    Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris .
    Aspirin DL-lysine
  • HY-14654A

    Acetylsalicylic acid lithium; ASA lithium

    COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin lithium
  • HY-14654C

    Acetylsalicylic acid calcium; ASA calcium

    COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin calcium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin calcium induces apoptosis. Aspirin calcium inhibits the activation of NF-κB. Aspirin calcium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin calcium
  • HY-W094747A

    Drug Intermediate Inflammation/Immunology
    Benzalazine is a 5-azo derivative of 5-Aminosalicylic Acid (HY-15027) that can be used for the research of ulcerative colitis and Crohn's disease of the large intestine. The benzalazine metabolite 5-ASA and the 5-ASA metabolite acetyl-5-aminosalicylic acid are excreted mainly with the faeces .
    Benzalazine
  • HY-15027S4

    5-ASA-d7; Mesalamie-d7; Mesalazie-d7

    Isotope-Labeled Compounds PPAR PAK Endogenous Metabolite NF-κB Inflammation/Immunology Cancer
    5-Aminosalicylic acid-d7 (5-ASA-d7; Mesalamie-d7; Mesalazie-d7) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .
    5-Aminosalicylic acid-d7
  • HY-B0174A
    Olsalazine
    1 Publications Verification

    Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
    Olsalazine
  • HY-112865

    ADVATE; BAY 81-8973; Kovaltry

    Factor VIII Others
    Octocog alfa (ADVATE; BAY 81-8973; Kovaltry) is a second-generation full-length recombinant factor VIII, as a antihemophilic factor .
    Octocog alfa
  • HY-B0174
    Olsalazine Disodium
    1 Publications Verification

    Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Olsalazine Disodium is an orally active prodrug of 5-ASA (HY-15027). Olsalazine Disodium can inhibit cells proliferation and induce apoptosis. Olsalazine Disodium can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine Disodium can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
    Olsalazine Disodium
  • HY-B0174AR

    Reference Standards Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Olsalazine (Standard) is an orally active prodrug of 5-ASA (HY-15027). Olsalazine (Standard) can inhibit cells proliferation and induce apoptosis. Olsalazine (Standard) can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine (Standard) can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
    Olsalazine (Standard)
  • HY-RS18745

    Small Interfering RNA (siRNA) Others

    Arsa Mouse Pre-designed siRNA Set A contains three designed siRNAs for Arsa gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Arsa Mouse Pre-designed siRNA Set A
    Arsa Mouse Pre-designed siRNA Set A
  • HY-B0174R

    Reference Standards Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Olsalazine Disodium (Standard) is an orally active prodrug of 5-ASA (HY-15027). Olsalazine Disodium (Standard) can inhibit cells proliferation and induce apoptosis. Olsalazine Disodium (Standard) can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine Disodium (Standard) can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
    Olsalazine Disodium (Standard)
  • HY-RS01034

    Small Interfering RNA (siRNA) Others

    ARSA Human Pre-designed siRNA Set A contains three designed siRNAs for ARSA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ARSA Human Pre-designed siRNA Set A
    ARSA Human Pre-designed siRNA Set A
  • HY-B0174AS

    Isotope-Labeled Compounds Apoptosis Others Metabolic Disease Inflammation/Immunology Cancer
    Olsalazine- 13C6 is the 13C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
    Olsalazine-13C6
  • HY-B0174AS1

    Isotope-Labeled Compounds Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Olsalazine-d3 is deuterated labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
    Olsalazine-d3
  • HY-167706

    GPR35 Inflammation/Immunology
    Diethyl-Lodoxamide is a highly potent GPR35 agonist with potential to inhibit inflammatory bowel disease. Diethyl-Lodoxamide activates GPR35 in humans, mice and rats, showing similar EC50 values. Diethyl-Lodoxamide can alleviate the clinical symptoms of DSS-induced inflammatory bowel disease in mouse models, and the effect is better than the traditional drug 5-ASA. The pharmaceutical properties of Diethyl-Lodoxamide have been optimized to better meet the requirements of drug design .
    Diethyl-Lodoxamide
  • HY-15027
    5-Aminosalicylic Acid
    20+ Cited Publications

    Mesalamine; 5-ASA; Mesalazine

    PPAR PAK NF-κB Endogenous Metabolite Inflammation/Immunology Cancer
    5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
    5-Aminosalicylic Acid
  • HY-B0174AS2

    Isotope-Labeled Compounds Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Olsalazine-d3, 15N is 15N and deuterated labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
    Olsalazine-d3,15N
  • HY-145453

    Interleukin Related Inflammation/Immunology
    Propacetamol is an orally active prodrug of Acetaminophen (HY-66005), which exerts antipyretic and analgesic effects after metabolism. Propacetamol reduces Aspirin (ASA) (HY-14654)-induced elevation of malondialdehyde (MDA) in gastric mucosa and plasma, regulates the levels of gastric mucosal glutathione (GSH and GSSG) to maintain cellular antioxidant defense, and increases gastric mucosal uric acid (UA) levels. Propacetamol exerts a dose-dependent protective effect against ASA-induced gastric mucosal damage in rats. Propacetamol can be used for the study of gastric mucosal injury by interfering with oxidative stress .
    Propacetamol
  • HY-66008

    N-Acetyl-5-aminosalicylic acid; N-Acetyl-ASA

    Drug Metabolite Inflammation/Immunology Cancer
    N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
    N-Acetyl mesalazine
  • HY-15027R

    Mesalamine (Standard); 5-ASA (Standard); Mesalazine (Standard)

    Reference Standards PPAR PAK NF-κB Endogenous Metabolite Inflammation/Immunology Cancer
    5-Aminosalicylic Acid (Standard) is the analytical standard of 5-Aminosalicylic Acid. This product is intended for research and analytical applications. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
    5-Aminosalicylic Acid (Standard)
  • HY-145453R

    Reference Standards Interleukin Related Inflammation/Immunology
    Propacetamol (Standard) is the analytical standard of Propacetamol (HY-145453). This product is intended for research and analytical applications. Propacetamol is an orally active prodrug of Acetaminophen (HY-66005), which exerts antipyretic and analgesic effects after metabolism. Propacetamol reduces Aspirin (ASA) (HY-14654)-induced elevation of malondialdehyde (MDA) in gastric mucosa and plasma, regulates the levels of gastric mucosal glutathione (GSH and GSSG) to maintain cellular antioxidant defense, and increases gastric mucosal uric acid (UA) levels. Propacetamol exerts a dose-dependent protective effect against ASA-induced gastric mucosal damage in rats. Propacetamol can be used for the study of gastric mucosal injury by interfering with oxidative stress .
    Propacetamol (Standard)
  • HY-131697

    NO Synthase Apoptosis Inflammation/Immunology
    FeTPPS, a 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrin iron III chloride peroxynitrite decomposition catalyst, possesses evident neuroprotective effects in a experimental model of spinal cord damage . FeTPPS acts as a peroxynitrite scavenger and anti-nitrating agent in vivo. FeTPPS reduces nitric oxide (NO) production and apoptosis process .
    FeTPPS
  • HY-66008R

    N-Acetyl-5-aminosalicylic acid (Standard); N-Acetyl-ASA (Standard)

    Drug Metabolite Reference Standards Inflammation/Immunology Cancer
    N-Acetyl mesalazine (Standard) (N-Acetyl-5-aminosalicylic acid (Standard)) is the analytical standard of N-Acetyl mesalazine (HY-66008). This product is intended for research and analytical applications. N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
    N-Acetyl mesalazine (Standard)
  • HY-164480

    IKK NF-κB Inflammation/Immunology Cancer
    GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) (HY-17363) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44 + CD24 - immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers .
    GTCpFE
  • HY-15027S1

    Mesalamine-d3; 5-ASA-d3; Mesalazine-d3

    Isotope-Labeled Compounds Endogenous Metabolite NF-κB PAK PPAR Inflammation/Immunology Cancer
    5-Aminosalicylic acid-d3 is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
    5-Aminosalicylic acid-d3
  • HY-66008S

    N-Acetyl-5-aminosalicylic acid-d3; N-Acetyl-ASA-d3

    Isotope-Labeled Compounds Drug Metabolite Inflammation/Immunology Cancer
    N-Acetyl mesalazine-d3 (N-Acetyl-5-aminosalicylic acid-d3) is the deuterium labeled N-Acetyl mesalazine (HY-66008). N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
    N-Acetyl mesalazine-d3
  • HY-15027S

    Mesalamine-d3 hydrochloride; 5-ASA-d3 hydrochloride; Mesalazine-d3 hydrochloride

    Isotope-Labeled Compounds PPAR PAK NF-κB Endogenous Metabolite Inflammation/Immunology Cancer
    5-Aminosalicylic Acid-d3 (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
    5-Aminosalicylic Acid-d3 hydrochloride
  • HY-66008S1

    N-Acetyl-5-aminosalicylic acid-d3-1; N-Acetyl-ASA-d3-1

    Isotope-Labeled Compounds Drug Metabolite Inflammation/Immunology Cancer
    N-Acetyl mesalazine-d3-1 (N-Acetyl-5-aminosalicylic acid-d3-1) is deuterium labeled N-Acetyl mesalazine (HY-66008). N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
    N-Acetyl mesalazine-d3-1
  • HY-15027S3

    Mesalamine-d3 disodium; 5-ASA-d3 disodium; Mesalazine-d3 disodium

    PPAR NF-κB Endogenous Metabolite PAK Isotope-Labeled Compounds Inflammation/Immunology
    5-Aminosalicylic acid-d3 disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
    5-Aminosalicylic acid-d3 disodium
  • HY-66008S2

    N-Acetyl-5-aminosalicylic acid-13C6; N-Acetyl-ASA-13C6

    Isotope-Labeled Compounds Drug Metabolite Inflammation/Immunology Cancer
    N-Acetyl mesalazine- 13C6 (N-Acetyl-5-aminosalicylic acid- 13C6) is a deuterated labeled N-Acetyl mesalazine (HY-66008). N-Acetyl mesalazine (N-Acetyl-5-aminosalicylic acid) is the primary intestinal metabolite of 5-Aminosalicylic Acid (HY-15027) and serves as a biomarker for evaluating the efficacy of 5-Aminosalicylic Acid (HY-15027). N-Acetyl mesalazine can scavenge free radicals, reduce DNA base hydroxylation, and ameliorate mucosal inflammation. N-Acetyl mesalazine can be used in the study of diseases such as colitis and colon cancer .
    N-Acetyl mesalazine-13C6
  • HY-15027S2

    Mesalamine-13C6; 5-ASA-13C6; Mesalazine-13C6

    PPAR PAK NF-κB Endogenous Metabolite Inflammation/Immunology
    5-Aminosalicylic acid- 13C6 is the 13C labeled 5-Aminosalicylic Acid . 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .
    5-Aminosalicylic acid-13C6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: